{"id":"flot-scheme","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Mucositis"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5809502","moleculeType":null,"molecularWeight":"573.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FLOT combines fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and docetaxel to target rapidly dividing cancer cells through multiple mechanisms including thymidylate synthase inhibition, DNA cross-linking, and microtubule disruption. The combination is designed to provide synergistic anti-tumor activity with improved efficacy compared to single-agent chemotherapy.","oneSentence":"FLOT is a chemotherapy combination regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:46.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (neoadjuvant and palliative treatment)"},{"name":"Gastroesophageal junction cancer"}]},"trialDetails":[{"nctId":"NCT05610332","phase":"PHASE3","title":"Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2022-11-01","conditions":"Locally Advanced Gastric Cancer","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FLOT scheme","genericName":"FLOT scheme","companyName":"Fujian Medical University","companyId":"fujian-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLOT is a chemotherapy combination regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Gastric cancer (neoadjuvant and palliative treatment), Gastroesophageal junction cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}